TARA
Protara Therapeutics, Inc.5.42
-0.08-1.45%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
290.44MP/E (TTM)
-Basic EPS (TTM)
-1.39Dividend Yield
0%Recent Filings
10-K
FY2025 results
Protara Therapeutics posted FY2025 net loss of $57.4M on $64.5M operating expenses, up from $44.6M loss and $49.2M expenses in FY2024, while bolstering cash to $197.9M via offerings. R&D surged 34% to $42.6M, fueled by ADVANCED-2 enrollment in NMIBC (TARA-002 hit 66% six-month CR in BCG-naïve cohort) and THRIVE-3 launch for IV Choline Chloride; no Q4 breakdowns disclosed. Cash burn accelerated to $56.4M amid trial ramps, yet liquidity funds operations into 2027. No dividends, buybacks or capex shifts noted. Clinical delays from FDA staffing cuts threaten momentum.
8-K
Q4 results, TARA-002 data
Protara Therapeutics reported Q4 and full-year 2025 results, highlighting ADVANCED-2 interim data with TARA-002 showing 68% complete response at six months in BCG-unresponsive NMIBC patients. Cash hit $197.9 million after an oversubscribed $86.3 million offering, funding operations into 2028. Enrollment completes 2H 2026. Strong runway powers pipeline.
8-K
TARA-002 hits 68% CR
Protara disclosed updated interim Phase 2 ADVANCED-2 data for TARA-002 in NMIBC, showing 68% six-month complete response in BCG-unresponsive patients (35 evaluable) and 67% in BCG-naïve (29 evaluable), with 100% durability from nine to 12 months among responders. No Grade 3+ treatment-related adverse events occurred. Enrollment completes in BCG-unresponsive cohort 2H 2026.
8-K
Option fully exercised, $86.3M raised
Protara Therapeutics closed the full exercise of underwriters' option on December 15, 2025, selling 1,956,521 additional shares at $5.75 each, bringing total gross proceeds to ~$86.3 million. Funds will fuel TARA-002 clinical development and other programs, plus working capital. Underwriters grabbed the full option fast.
8-K
Protara closes $75M offering
Protara Therapeutics closed a $75 million public offering of 13 million shares at $5.75 each on December 8, 2025, after agreeing with J.P. Morgan, TD Securities, and Piper Sandler on December 4. Net proceeds will fund TARA-002 clinical development and other programs, plus working capital. Underwriters hold a 30-day option for 1.96 million more shares. 60-day lock-ups bind insiders.
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
ATRA
Atara Biotherapeutics, Inc.
17.58-0.37
BCAX
Bicara Therapeutics Inc.
18.15-0.21
FATE
Fate Therapeutics, Inc.
1.09-0.03
PPCB
Propanc Biopharma, Inc.
0.73-0.03
PROK
ProKidney Corp.
2.20+0.12
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
PVCT
Provectus Biopharmaceuticals, I
0.06+0.00
SVRA
Savara, Inc.
6.43-0.18
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02